Mast-Cell Stabilizing Effects of Olopatadine
This study has been completed.
Sponsor:
Alcon Research
Information provided by:
Alcon Research
ClinicalTrials.gov Identifier:
NCT00389025
First received: October 13, 2006
Last updated: January 4, 2010
Last verified: January 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To assess the effects of olopatadine of the release of mast cell histamine
| Condition | Intervention | Phase |
|---|---|---|
|
Allergic Conjunctivitis |
Drug: Olopatadine (generic name) |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Single Group Assignment Masking: Double-Blind Primary Purpose: Prevention |
| Official Title: | Mast-Cell Stabilizing Effects of Olopatadine |
Resource links provided by NLM:
Further study details as provided by Alcon Research:
Primary Outcome Measures:
- Tear histamine
Secondary Outcome Measures:
- Tear cytology, subject evaluation of ocular itching, investigators evaluation of ocular redness
| Enrollment: | 24 |
| Study Start Date: | October 2006 |
| Primary Completion Date: | April 2007 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Asymptomatic and not using any topical or systemic medication
Exclusion Criteria:
- Age
Contacts and Locations
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00389025 History of Changes |
| Other Study ID Numbers: | C-05-30 |
| Study First Received: | October 13, 2006 |
| Last Updated: | January 4, 2010 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Alcon Research:
|
Subject with clinical history of seasonal allergic conjunctivitis |
Additional relevant MeSH terms:
|
Conjunctivitis Conjunctivitis, Allergic Conjunctival Diseases Eye Diseases Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Olopatadine Histamine H1 Antagonists, Non-Sedating Histamine H1 Antagonists Histamine Antagonists Histamine Agents Neurotransmitter Agents |
Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Anti-Allergic Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Anti-Inflammatory Agents Antirheumatic Agents Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 16, 2013